Sander, K;
Lashley, T;
Gami, P;
Gendron, T;
Lythgoe, MF;
Rohrer, JD;
Schott, JM;
... Årstad, E; + view all
(2016)
Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.
Alzheimer's & Dementia
, 12
(11)
pp. 1116-1124.
10.1016/j.jalz.2016.01.003.
Preview |
Text (Article)
Sander_Alzheimer Dementia 2016_accepted manuscript.pdf - Submitted Version Download (4MB) | Preview |
Preview |
Text (Supporting Information)
Sander_Alzheimer Dementia 2016_supporting information.pdf - Supplemental Material Download (1MB) | Preview |
Abstract
INTRODUCTION: Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [(18)F]AV-1451 in a range of dementias. METHODS: Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias. RESULTS: [(18)F]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteinopathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups. DISCUSSION: [(18)F]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non-tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic.
Archive Staff Only
 |
View Item |
